|
· Pipeline now includes 11 new molecular entities in Phase III or registration; almost double compared with the previous
|
|
year.
|
|
· Integration of the Bristol-Myers Squibb share of the diabetes alliance occurring at pace; business combination
|
|
transaction completed on 1 February 2014.
|
|
· The key growth platforms Brilinta, the diabetes franchise, respiratory, Emerging Markets and Japan delivered an incremental $1.2 billion of revenue at CER in 2013. This was more than offset by the impact of patent expiries, which reduced revenue by $2.2 billion at CER. In the quarter, revenue in China increased by 21 percent at CER.
|
|
· The decline in EPS was greater than the decline in revenue primarily due to the investment in the Company's key growth platforms and strengthened pipeline.
|
|
· The impairment of Bydureon ($1,758 million) in the fourth quarter reduced Reported earnings per share by $1.10, resulting in a Reported loss per share for the quarter of $0.42.
|
|
· Farxiga (US) and Xigduo (EU) approved for type 2 diabetes
|
|
· Olaparib (EU) and naloxegol (EU & US) submitted for regulatory review
|
|
· Benralizumab, selumetinib, olaparib and moxetumomab commenced Phase III trials
|
|
· Multiple ongoing trials with innovative immuno-oncology portfolio
|
Group
|
4th Quarter
2013
$m
|
Actual
%
|
CER
%
|
Full Year
2013
$m
|
Actual
%
|
CER
%
|
|||
Revenue
|
6,844
|
(6)
|
(4)
|
25,711
|
(8)
|
(6)
|
|||
Core*
|
|||||||||
Operating Profit
|
1,983
|
(29)
|
(26)
|
8,390
|
(25)
|
(22)
|
|||
Earnings per Share
|
$1.23
|
(28)
|
(25)
|
$5.05
|
(26)
|
(23)
|
|||
Reported
|
|||||||||
Operating (Loss)/Profit
|
(591)
|
(130)
|
(128)
|
3,712
|
(54)
|
(51)
|
|||
(Loss)/Earnings per Share
|
($0.42)
|
(135)
|
(132)
|
$2.04
|
(59)
|
(55)
|
|||
* See Operating and Financial Review for a definition of Core financial measures and a reconciliation of Core to Reported financial measures.
|
|||||||||
Reported
2013
|
Restructuring
|
Intangible
Amortisation
|
Intangible
Impairments
|
Legal
Provisions
& Other
|
Core
2013
|
Restated Core
2012
|
Actual
%
|
CER
%
|
|
Revenue
|
6,844
|
-
|
-
|
-
|
-
|
6,844
|
7,282
|
(6)
|
(4)
|
Cost of Sales
|
(1,440)
|
22
|
129
|
-
|
-
|
(1,289)
|
(1,210)
|
||
Gross Profit
|
5,404
|
22
|
129
|
-
|
-
|
5,555
|
6,072
|
(9)
|
(7)
|
% sales
|
79.0%
|
81.2%
|
83.4%
|
-2.2
|
-2.4
|
||||
Distribution
|
(72)
|
-
|
-
|
-
|
-
|
(72)
|
(79)
|
(9)
|
(7)
|
% sales
|
1.1%
|
1.1%
|
1.1%
|
-
|
-
|
||||
R&D
|
(1,429)
|
84
|
15
|
143
|
(18)
|
(1,205)
|
(1,180)
|
2
|
2
|
% sales
|
20.9%
|
17.6%
|
16.2%
|
-1.4
|
-1.0
|
||||
SG&A
|
(4,642)
|
279
|
233
|
1,662
|
(15)
|
(2,483)
|
(2,204)
|
13
|
14
|
% sales
|
67.8%
|
36.3%
|
30.3%
|
-6.0
|
-5.7
|
||||
Other Income
|
148
|
-
|
40
|
-
|
-
|
188
|
186
|
1
|
1
|
% sales
|
2.2%
|
2.8%
|
2.6%
|
+0.2
|
+0.1
|
||||
Operating (Loss)/Profit
|
(591)
|
385
|
417*
|
1,805
|
(33)
|
1,983
|
2,795
|
(29)
|
(26)
|
% sales
|
-8.6%
|
29.0%
|
38.4%
|
-9.4
|
-9.0
|
||||
Net Finance Expense
|
(124)
|
-
|
-
|
-
|
-
|
(124)
|
(128)
|
||
(Loss)/Profit before Tax
|
(715)
|
385
|
417
|
1,805
|
(33)
|
1,859
|
2,667
|
(30)
|
(28)
|
Taxation
|
195
|
(70)
|
(59)*
|
(385)
|
4**
|
(315)
|
(529)
|
||
(Loss)/Profit after Tax
|
(520)
|
315
|
358
|
1,420
|
(29)
|
1,544
|
2,138
|
(28)
|
(25)
|
Non-controlling Interests
|
(4)
|
-
|
-
|
-
|
-
|
(4)
|
(13)
|
||
Net (Loss)/Profit
|
(524)
|
315
|
358
|
1,420
|
(29)
|
1,540
|
2,125
|
(28)
|
(25)
|
Weighted Average Shares
|
1,254
|
1,254
|
1,254
|
1,254
|
1,254
|
1,254
|
1,246
|
||
(Loss)/Earnings per Share
|
(0.42)
|
0.26
|
0.28
|
1.13
|
(0.02)
|
1.23
|
1.71
|
(28)
|
(25)
|
*
|
Intangible amortisation includes Merck related amortisation, of which $98 million carries no tax adjustment.
|
**
|
Legal Provisions & Other includes $14 million which carries no tax adjustment.
|
Reported
2013
|
Restructuring
|
Intangible
Amortisation
|
Intangible
Impairments
|
Legal
Provisions
& Other
|
Core
2013
|
Restated Core
2012
|
Actual
%
|
CER
%
|
|
Revenue
|
25,711
|
-
|
-
|
-
|
-
|
25,711
|
27,973
|
(8)
|
(6)
|
Cost of Sales
|
(5,261)
|
126
|
502
|
-
|
-
|
(4,633)
|
(4,932)
|
||
Gross Profit
|
20,450
|
126
|
502
|
-
|
-
|
21,078
|
23,041
|
(9)
|
(7)
|
% sales
|
79.5%
|
82.0%
|
82.4%
|
-0.4
|
-0.5
|
||||
Distribution
|
(306)
|
-
|
-
|
-
|
-
|
(306)
|
(320)
|
(4)
|
(3)
|
% sales
|
1.2%
|
1.2%
|
1.2%
|
-
|
-
|
||||
R&D
|
(4,821)
|
490
|
30
|
50
|
(18)
|
(4,269)
|
(4,241)
|
1
|
1
|
% sales
|
18.7%
|
16.6%
|
15.1%
|
-1.5
|
-1.1
|
||||
SG&A
|
(12,206)
|
805
|
902
|
1,662
|
(28)
|
(8,865)
|
(8,389)
|
6
|
7
|
% sales
|
47.5%
|
34.5%
|
30.0%
|
-4.5
|
-4.3
|
||||
Other Income
|
595
|
-
|
157
|
-
|
-
|
752
|
1,068
|
(30)
|
(30)
|
% sales
|
2.3%
|
2.9%
|
3.8%
|
-0.9
|
-1.0
|
||||
Operating Profit
|
3,712
|
1,421
|
1,591*
|
1,712
|
(46)
|
8,390
|
11,159
|
(25)
|
(22)
|
% sales
|
14.4%
|
32.6%
|
39.9%
|
-7.3
|
-6.9
|
||||
Net Finance Expense
|
(445)
|
-
|
-
|
-
|
-
|
(445)
|
(502)
|
||
Profit before Tax
|
3,267
|
1,421
|
1,591
|
1,712
|
(46)
|
7,945
|
10,657
|
(25)
|
(23)
|
Taxation
|
(696)
|
(302)
|
(256)*
|
(364)
|
7**
|
(1,611)
|
(2,022)
|
||
Profit after Tax
|
2,571
|
1,119
|
1,335
|
1,348
|
(39)
|
6,334
|
8,635
|
(27)
|
(24)
|
Non-controlling Interests
|
(15)
|
-
|
-
|
-
|
-
|
(15)
|
(30)
|
||
Net Profit
|
2,556
|
1,119
|
1,335
|
1,348
|
(39)
|
6,319
|
8,605
|
(27)
|
(24)
|
Weighted Average Shares
|
1,252
|
1,252
|
1,252
|
1,252
|
1,252
|
1,252
|
1,261
|
||
Earnings per Share
|
2.04
|
0.90
|
1.06
|
1.08
|
(0.03)
|
5.05
|
6.83
|
(26)
|
(23)
|
*
|
Intangible amortisation includes Merck related amortisation, of which $392 million carries no tax adjustment.
|
**
|
Legal Provisions & Other includes $14 million which carries no tax adjustment.
|
|
· It expects a low-to-mid single digit percentage decline in revenue at CER for 2014.
|
|
· In percentage terms, Core EPS for 2014 is expected to decline in the teens at CER.
|
|
· The Company expects revenues in 2017 will be broadly in line with 2013.
|
Fourth Quarter
|
Full Year
|
||||||||
2013
|
2012
|
CER
|
2013
|
2012
|
CER
|
||||
$m
|
$m
|
%
|
$m
|
$m
|
%
|
||||
Cardiovascular
|
|||||||||
Crestor
|
1,463
|
1,622
|
(8)
|
5,622
|
6,253
|
(8)
|
|||
Onglyza
|
93
|
88
|
6
|
378
|
323
|
17
|
|||
Byetta
|
54
|
47
|
17
|
206
|
74
|
181
|
|||
Bydureon
|
49
|
26
|
88
|
151
|
37
|
308
|
|||
Forxiga
|
3
|
-
|
n/m
|
10
|
-
|
n/m
|
|||
Brilinta/Brilique
|
92
|
38
|
139
|
283
|
89
|
216
|
|||
Atacand
|
134
|
202
|
(33)
|
611
|
1,009
|
(39)
|
|||
Seloken/Toprol-XL
|
170
|
256
|
(32)
|
750
|
918
|
(18)
|
|||
Gastrointestinal
|
|||||||||
Nexium
|
991
|
1,047
|
(3)
|
3,872
|
3,944
|
-
|
|||
Losec/Prilosec
|
122
|
156
|
(18)
|
486
|
710
|
(28)
|
|||
Respiratory & Inflammation
|
|||||||||
Symbicort
|
976
|
891
|
11
|
3,483
|
3,194
|
10
|
|||
Pulmicort
|
245
|
242
|
3
|
867
|
866
|
1
|
|||
Oncology
|
|||||||||
Zoladex
|
247
|
271
|
1
|
996
|
1,093
|
-
|
|||
Arimidex
|
86
|
122
|
(23)
|
351
|
543
|
(30)
|
|||
Casodex
|
95
|
112
|
(4)
|
376
|
454
|
(7)
|
|||
Iressa
|
158
|
160
|
5
|
647
|
611
|
11
|
|||
Faslodex
|
182
|
175
|
6
|
681
|
654
|
6
|
|||
Neuroscience
|
|||||||||
Seroquel
|
372
|
476
|
(22)
|
1,682
|
2,803
|
(39)
|
|||
Seroquel IR
|
35
|
94
|
(64)
|
345
|
1,294
|
(72)
|
|||
Seroquel XR
|
337
|
382
|
(12)
|
1,337
|
1,509
|
(12)
|
|||
Zomig
|
35
|
39
|
(5)
|
134
|
182
|
(23)
|
|||
Vimovo
|
24
|
18
|
39
|
91
|
65
|
42
|
|||
Infection and other
|
|||||||||
Synagis
|
515
|
503
|
2
|
1,060
|
1,038
|
2
|
|||
Merrem
|
77
|
106
|
(25)
|
293
|
396
|
(24)
|
|||
FluMist/Fluenz
|
50
|
32
|
56
|
245
|
181
|
35
|
·
|
In the US, Crestor sales in the fourth quarter were $779 million, down 10 percent, on a 7 percent decline in total prescriptions combined with some impact from lower stocking and slightly lower realised net price. Crestor share of total prescriptions at 10.6 percent has been resilient in a competitive generic market. Crestor sales for the full year in the US were down 8 percent to $2,912 million.
|
·
|
Crestor sales in the Rest of World in the fourth quarter were down 6 percent to $684 million, reflecting the loss of exclusivity in Australia and Canada. Excluding these markets, ROW sales were up by 2 percent, driven by growth in China. Crestor sales in the Rest of World for the full year were down 9 percent to $2,710 million.
|
·
|
Alliance revenue from the Onglyza collaboration with Bristol-Myers Squibb was up 6 percent in the fourth quarter to $93 million, with all growth coming in markets outside the US, where revenue was up 20 percent to $30 million. US revenue was flat at $63 million, with favourable price realisation fully offsetting a share decline largely driven by a less favourable formulary position.
|
·
|
Market share of total prescriptions in the US for the Onglyza franchise in the DPP4 market was 15.8 percent in December, down 2 points this year primarily related to formulary position, with little impact realised from the launch of new entrants. AstraZeneca's share of worldwide alliance revenue for the full year was $378 million, up 17 percent.
|
·
|
Alliance revenue for Forxiga was $3 million in the quarter and $10 million for the full year, all in Europe, where there has been good physician acceptance since approval in November 2012, but a challenging reimbursement climate to navigate.
|
·
|
The Company's share of Byetta and Bydureon revenues was $103 million in the fourth quarter; comprised of $76 million in the US and $27 million in ROW. There were no revenues recorded in ROW in 2012 as the alliance only assumed responsibility for promotion outside the US in April 2013. In the US, total prescriptions for Bydureon were up 49 percent over the fourth quarter 2012 and total prescriptions for Byetta down 35 percent resulting in a 9 percent decline for the exenatide franchise over the same period. However, the quarter-over-quarter total prescription volume decline stopped in the fourth quarter on improved new-to-brand share for Bydureon. The Company's share of worldwide revenue for the exenatide products was $357 million for the full year.
|
·
|
Global sales of Brilinta/Brilique were $92 million in the fourth quarter, up from $75 million in the third quarter 2013. More than half of the sales were in Europe where fourth quarter sales have more than doubled since last year. Performance in Canada, Australia and the Emerging Markets is also contributing to brand revenue growth, representing more than 18 percent of sales in the quarter. Worldwide sales for Brilinta/Brilique were $283 million for the full year.
|
·
|
US sales of Brilinta in the fourth quarter were $24 million, 33 percent above the third quarter 2013. Dispensed demand growth of 17 percent was in line with sales growth when the impact of reserve adjustments posted in the third quarter is excluded. Total prescription share for Brilinta in the US was 1.85 percent in December, growing more than a full share point in the year. This growth was driven by new to brand share of 6.8 percent, growth of which was accelerating before the announcement of a Civil Investigative Demand related to the PLATO trial. The Company is fully cooperating with the inquiry and is confident in the integrity of the PLATO study. Full year sales of Brilinta in the US were $73 million.
|
·
|
US sales of Atacand were down 69 percent in the fourth quarter to $10 million, as both forms of the brand now have generic competition. Sales for the full year were down 52 percent to $72 million.
|
·
|
Atacand sales in other markets were down 26 percent to $124 million in the fourth quarter, largely due to the loss of exclusivity in developed markets and slight decrease in Emerging Markets. Sales in ROW for the full year were $539 million, down 36 percent.
|
·
|
US sales of the Toprol-XL product range, which includes sales of the authorised generic, decreased by 81 percent in the fourth quarter to $19 million, driven by lower prescription volume and lower net realised price following the launch of a fourth generic late in 2012. The decline in the quarter was exacerbated by a favourable returns adjustment in the prior year. Sales for the full year in the US were down 59 percent to $131 million.
|
·
|
Sales of Seloken in other markets in the fourth quarter were down 3 percent to $151 million. Sales for the full year were up 5 percent to $619 million.
|
·
|
In the US, Nexium sales in the fourth quarter were $545 million, down 9 percent compared with the fourth quarter last year. Dispensed retail tablet volume declined by around 11 percent. Nexium sales in the US for the full year were down 7 percent to $2,123 million.
|
·
|
As a result of various patent litigation settlements, several generic companies were granted a license to enter the US market with their proposed ANDA versions of generic esomeprazole on 27 May 2014, subject to regulatory approval, or earlier, in certain circumstances. In line with the Company's standard practice, a returns reserve will be taken against the estimated trade inventories of Nexium at the time of the first generic launch. The Company will also move the brand to demand based accounting, wherein revenue will be recognised based on demand sales, indicated by dispensed prescription demand, rather than ex-factory shipments. Therefore, Nexium revenue in 2014 will reflect this accounting treatment, the loss of market share to generic substitution, and the impact of channel destocking as trade inventories contract to adjust to the declining sales trend.
|
·
|
Nexium sales in other markets in the fourth quarter increased by 5 percent to $446 million. Sales in Europe were down 12 percent, largely the result of generic competition. Sales in Established Rest of World were up 30 percent, driven by a doubling of sales in Japan. Sales in Emerging Markets decreased by 5 percent, as growth in China of 29 percent was more than offset by declines in other markets. Nexium sales in other markets were up 10 percent for the full year to $1,749 million.
|
·
|
Losec sales in markets outside the US were down 20 percent in the fourth quarter to $115 million, largely on lower sales in Japan. Global sales for the full year were down 28 percent to $486 million.
|
·
|
Symbicort sales in the fourth quarter in the US were $350 million, a 28 percent increase over the fourth quarter last year. Total prescriptions for Symbicort were up 17 percent in the relatively flat market for fixed combination products. Symbicort share of total prescriptions for fixed combination products reached 26.2 percent in December 2013, up 3.9 percentage points since December 2012. Market share of patients new to brand was 35.3 percent in December, up 6.8 points from December 2012, with current weekly share of 41.1 percent reflecting the effect of 2014 formulary changes in the fixed combination market. Symbicort sales in the US for the full year were up 23 percent to $1,233 million.
|
·
|
Symbicort sales in ROW in the fourth quarter were $626 million, up 3 percent, on 21 percent growth in Emerging Markets, driven by China, up 122 percent. Reported sales decline of 5 percent in Japan reflects the phasing of shipments to our marketing partner; in market demand is up 22 percent. Market share in Japan is up 3.8 percentage points since the beginning of the year. Sales in other established markets were broadly flat. Symbicort sales in the Rest of World for the full year were up 4 percent to $2,250 million.
|
·
|
US sales of Pulmicort were up 5 percent in the fourth quarter to $59 million. Sales for the full year were down 4 percent to $224 million.
|
·
|
Pulmicort sales in the Rest of World were up 2 percent in the fourth quarter to $186 million, largely on a 28 percent increase in China. Full year sales of Pulmicort in China were $243 million, a growth of 21 percent. Rest of World sales for Pulmicort for the full year were $643 million, 3 percent higher than last year.
|
·
|
Arimidex sales for the full year were down 30 percent worldwide to $351 million, as a result of loss of exclusivity. Sales in Japan, which account for 38 percent of global revenue, were down 28 percent for the full year. US Sales now represent less than 2 percent of total revenue.
|
·
|
Global Casodex sales for the full year were down 7 percent to $376 million. Sales in Japan, which account for 57 percent of global revenue, were down 10 percent for the full year.
|
·
|
Iressa sales in the fourth quarter were up 5 percent to $158 million. Sales in Japan were flat for the quarter, but were up 7 percent for the year and represent 29 percent of global sales of the brand. Sales in Emerging Markets were up 11 percent in the fourth quarter, driven by a 10 percent increase in China, which now represents 20 percent of global sales for the year. Worldwide sales of Iressa for the full year increased by 11 percent to $647 million.
|
·
|
Global Faslodex sales were up 6 percent for the fourth quarter and full year. Worldwide sales for the year of $681 million were driven by steady growth in the US of 5 percent to $324 million, along with strong growth in ROW markets, such as Japan (up 24 percent) and Latin America (up 26 percent).
|
·
|
In the US, sales of Seroquel IR for the full year were -$17 million, as unfavourable adjustments taken for the Medicaid liability and the estimated trade inventory reserve more than offset current year revenue.
|
·
|
Sales of Seroquel XR in the US were down 9 percent to $194 million in the fourth quarter. Total prescription volume was down 6 percent. Seroquel XR share of total prescriptions has shown recent signs of stabilising at 4.2 percent, stemming the decline following the launch of quetiapine IR generics at the end of March 2012. US sales of Seroquel XR for the full year were down 8 percent to $743 million.
|
·
|
Sales of Seroquel IR in the Rest of World were down 50 percent to $54 million in the fourth quarter, driven by partner ordering patterns in Japan in conjunction with a price concession on trade inventory posted in the quarter. Sales in the Rest of World for Seroquel IR for the full year were down 36 percent to $362 million.
|
·
|
Sales of Seroquel XR in the Rest of World were down 17 percent to $143 million in the fourth quarter. Sales in established markets (Europe and Established ROW) were down 23 percent, as growth in France was more than offset by declines in several markets following the patent invalidation actions and at risk launch in some EU markets. Sales in Emerging Markets were up 21 percent in the quarter. Seroquel XR sales in the Rest of World for the full year were $594 million, down 15 percent.
|
·
|
Sales of Vimovo in the fourth quarter were $24 million, comprised of $3 million in the US and $21 million in the Rest of the World. The Company divested its rights to Vimovo in the US in November 2013. Global sales for the full year were $91 million.
|
·
|
Synagis sales in the US were down 1 percent to $300 million in the fourth quarter. Outside the US, Synagis sales were up 8 percent to $215 million. Global full year sales were up 2 percent to $1,060 million
|
·
|
Sales of Merrem for the full year were down 24 percent to $293 million, as a result of generic competition in many markets.
|
·
|
Sales of FluMist/Fluenz in the fourth quarter were $50 million, of which $22 million were in the US and $23 million in the UK. Global full year sales were up 35 percent to $245 million, driven by good reception for the launch of FluMist Quadrivalent/Fluenz in the US with sales of $199 million and effective implementation of vaccination policy programs in the UK with sales of $38 million.
|
Fourth Quarter
|
Full Year
|
|||||||
2013
|
2012
|
% Change
|
2013
|
2012
|
% Change
|
|||
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
US
|
2,634
|
2,823
|
(7)
|
(7)
|
9,691
|
10,655
|
(9)
|
(9)
|
Europe1
|
1,822
|
1,790
|
2
|
(2)
|
6,658
|
7,143
|
(7)
|
(9)
|
Established ROW2
|
1,023
|
1,347
|
(24)
|
(10)
|
3,973
|
5,080
|
(22)
|
(10)
|
Japan
|
668
|
860
|
(22)
|
(4)
|
2,485
|
2,904
|
(14)
|
4
|
Canada
|
161
|
209
|
(23)
|
(19)
|
637
|
1,090
|
(42)
|
(40)
|
Other Established ROW
|
194
|
278
|
(30)
|
(23)
|
851
|
1,086
|
(22)
|
(18)
|
Emerging Markets3
|
1,365
|
1,322
|
3
|
6
|
5,389
|
5,095
|
6
|
8
|
China
|
477
|
384
|
24
|
21
|
1,840
|
1,512
|
22
|
19
|
Total
|
6,844
|
7,282
|
(6)
|
(4)
|
25,711
|
27,973
|
(8)
|
(6)
|
1Europe comprises Western Europe and many markets that were formerly reported in Emerging Rest of World.
|
||||||||
2Established ROW comprises Canada, Japan, Australia and New Zealand.
|
||||||||
3Emerging Markets comprises all of the remaining Rest of World markets, including Brazil, China, India, Mexico, Russia, and Turkey.
|
·
|
In the US, revenue was down 7 percent in the fourth quarter, largely driven by generic competition on Atacand and the Toprol-XL franchise. There was strong revenue growth for Symbicort and Brilinta; however this was offset by continued decline of Nexium volume. Nexium and Crestor were also unfavourably impacted by an adjustment to the Medicare Coverage Gap liability.
|
·
|
Revenue in Europe was down 2 percent in the fourth quarter. Revenue increases for Brilique and Synagis across most markets and Fluenz in the UK could not offset declines related to generic competition on several brands including Seroquel, Atacand, Nexium and Merrem.
|
·
|
Revenue in Established ROW was down 10 percent in the fourth quarter, with more than half of the decline driven by generic competition for Crestor and Atacand in Australia and Seroquel XR, Nexium and Crestor in Canada. Revenue in Japan was down 4 percent, as growth of Nexium was more than offset by declines of Losec and Seroquel IR.
|
·
|
Revenue in Emerging Markets was up 6 percent in the fourth quarter, driven by 21 percent growth in China on strong sales of Crestor, Pulmicort and Nexium. Revenue increased by 17 percent in South Korea. Emerging Markets growth in the quarter was impacted by inventory adjustments in Mexico. Excluding these adjustments, growth in Emerging Markets was 8 percent in the quarter.
|
For the year ended 31 December
|
2013
$m
|
Restated*
2012
$m
|
||
Revenue
|
25,711
|
27,973
|
||
Cost of sales
|
(5,261)
|
(5,393)
|
||
Gross profit
|
20,450
|
22,580
|
||
Distribution costs
|
(306)
|
(320)
|
||
Research and development expense **
|
(4,821)
|
(5,243)
|
||
Selling, general and administrative costs **
|
(12,206)
|
(9,839)
|
||
Other operating income and expense
|
595
|
970
|
||
Operating profit
|
3,712
|
8,148
|
||
Finance income
|
50
|
42
|
||
Finance expense
|
(495)
|
(544)
|
||
Profit before tax
|
3,267
|
7,646
|
||
Taxation
|
(696)
|
(1,376)
|
||
Profit for the period
|
2,571
|
6,270
|
||
Other comprehensive income
|
||||
Items that will not be reclassified to profit or loss
|
||||
Remeasurement of the defined benefit pension liability
|
8
|
(13)
|
||
Tax on items that will not be reclassified to profit or loss
|
(82)
|
(65)
|
||
(74)
|
(78)
|
|||
Items that may be reclassified subsequently to profit or loss
|
||||
Foreign exchange arising on consolidation
|
(166)
|
106
|
||
Foreign exchange differences on borrowings designated in net investment hedges
|
(58)
|
(46)
|
||
Fair value movements on derivatives designated in net investment hedges
|
111
|
76
|
||
Amortisation of loss on cash flow hedge
|
1
|
1
|
||
Net available for sale gains taken to equity
|
69
|
72
|
||
Tax on items that may be reclassified subsequently to profit or loss
|
4
|
4
|
||
(39)
|
213
|
|||
Other comprehensive income for the period, net of tax
|
(113)
|
135
|
||
Total comprehensive income for the period
|
2,458
|
6,405
|
||
Profit attributable to:
|
||||
Owners of the parent
|
2,556
|
6,240
|
||
Non-controlling interests
|
15
|
30
|
||
2,571
|
6,270
|
|||
Total comprehensive income attributable to:
|
||||
Owners of the parent
|
2,470
|
6,395
|
||
Non-controlling interests
|
(12)
|
10
|
||
2,458
|
6,405
|
|||
Basic earnings per $0.25 Ordinary Share
|
$2.04
|
$4.95
|
||
Diluted earnings per $0.25 Ordinary Share
|
$2.04
|
$4.94
|
||
Weighted average number of Ordinary Shares in issue (millions)
|
1,252
|
1,261
|
||
Diluted weighted average number of Ordinary Shares in issue (millions)
|
1,254
|
1,264
|
|
** In 2013, the Company recognised intangible asset impairments related to Bydureon of $138 million in research and development expense and $1,620 million in selling, general and administrative costs.
|
For the quarter ended 31 December
|
2013
$m
|
Restated*
2012
$m
|
||
Revenue
|
6,844
|
7,282
|
||
Cost of sales
|
(1,440)
|
(1,398)
|
||
Gross profit
|
5,404
|
5,884
|
||
Distribution costs
|
(72)
|
(79)
|
||
Research and development expense **
|
(1,429)
|
(1,320)
|
||
Selling, general and administrative costs **
|
(4,642)
|
(2,669)
|
||
Other operating income and expense
|
148
|
148
|
||
Operating (loss)/profit
|
(591)
|
1,964
|
||
Finance income
|
13
|
15
|
||
Finance expense
|
(137)
|
(143)
|
||
(Loss)/profit before tax
|
(715)
|
1,836
|
||
Taxation
|
195
|
(316)
|
||
(Loss)/profit for the period
|
(520)
|
1,520
|
||
Other comprehensive income
|
||||
Items that will not be reclassified to profit or loss
|
||||
Remeasurement of the defined benefit pension liability
|
247
|
145
|
||
Tax on items that will not be reclassified to profit or loss
|
(44)
|
(47)
|
||
203
|
98
|
|||
Items that may be reclassified subsequently to profit or loss
|
||||
Foreign exchange arising on consolidation
|
(26)
|
(109)
|
||
Foreign exchange differences on borrowings designated in net investment hedges
|
(35)
|
(21)
|
||
Fair value movements on derivatives designated in net investment hedges
|
51
|
76
|
||
Net available for sale gains taken to equity
|
10
|
33
|
||
Tax on items that may be reclassified subsequently to profit or loss
|
3
|
1
|
||
3
|
(20)
|
|||
Other comprehensive income for the period, net of tax
|
206
|
78
|
||
Total comprehensive income for the period
|
(314)
|
1,598
|
||
(Loss)/profit attributable to:
|
||||
Owners of the parent
|
(524)
|
1,507
|
||
Non-controlling interests
|
4
|
13
|
||
(520)
|
1,520
|
|||
Total comprehensive income attributable to:
|
||||
Owners of the parent
|
(315)
|
1,603
|
||
Non-controlling interests
|
1
|
(5)
|
||
(314)
|
1,598
|
|||
Basic (loss)/earnings per $0.25 Ordinary Share
|
($0.42)
|
$1.21
|
||
Diluted (loss)/earnings per $0.25 Ordinary Share
|
($0.42)
|
$1.21
|
||
Weighted average number of Ordinary Shares in issue (millions)
|
1,254
|
1,246
|
||
Diluted weighted average number of Ordinary Shares in issue (millions)
|
1,256
|
1,248
|
|
** In 2013, the Company recognised intangible asset impairments related to Bydureon of $138 million in research and development expense and $1,620 million in selling, general and administrative costs.
|
|
|
|
Condensed Consolidated Statement of Financial Position
|
At 31 Dec 2013
$m
|
Restated*
At 31 Dec 2012
$m
|
|||||
ASSETS
Non-current assets
|
||||||
Property, plant and equipment
|
5,818
|
6,089
|
||||
Goodwill
|
9,981
|
9,898
|
||||
Intangible assets
|
16,047
|
16,448
|
||||
Derivative financial instruments
|
365
|
389
|
||||
Other investments
|
281
|
199
|
||||
Other receivables
|
1,867
|
352
|
||||
Deferred tax assets
|
1,205
|
1,111
|
||||
35,564
|
34,486
|
|||||
Current assets
|
||||||
Inventories
|
1,909
|
2,061
|
||||
Trade and other receivables
|
7,879
|
7,629
|
||||
Other investments
|
796
|
823
|
||||
Derivative financial instruments
|
40
|
31
|
||||
Income tax receivable
|
494
|
803
|
||||
Cash and cash equivalents
|
9,217
|
7,701
|
||||
20,335
|
19,048
|
|||||
Total assets
|
55,899
|
53,534
|
||||
LIABILITIES
Current liabilities
|
||||||
Interest-bearing loans and borrowings
|
(1,788)
|
(901)
|
||||
Trade and other payables
|
(10,362)
|
(9,221)
|
||||
Derivative financial instruments
|
(2)
|
(3)
|
||||
Provisions
|
(823)
|
(916)
|
||||
Income tax payable
|
(3,076)
|
(2,862)
|
||||
(16,051)
|
(13,903)
|
|||||
Non-current liabilities
|
||||||
Interest-bearing loans and borrowings
|
(8,588)
|
(9,409)
|
||||
Derivative financial instruments
|
(1)
|
-
|
||||
Deferred tax liabilities
|
(2,827)
|
(2,576)
|
||||
Retirement benefit obligations
|
(2,261)
|
(2,271)
|
||||
Provisions
|
(566)
|
(428)
|
||||
Other payables
|
(2,352)
|
(1,001)
|
||||
(16,595)
|
(15,685)
|
|||||
Total liabilities
|
(32,646)
|
(29,588)
|
||||
Net assets
|
23,253
|
23,946
|
||||
EQUITY
|
||||||
Capital and reserves attributable to equity holders of the Company
|
||||||
Share capital
|
315
|
312
|
||||
Share premium account
|
3,983
|
3,504
|
||||
Other reserves
|
1,966
|
1,960
|
||||
Retained earnings
|
16,960
|
17,955
|
||||
23,224
|
23,731
|
|||||
Non-controlling interests
|
29
|
215
|
||||
Total equity
|
23,253
|
23,946
|
For the year ended 31 December
|
2013
$m
|
Restated*
2012
$m
|
||
Cash flows from operating activities
|
||||
Profit before tax
|
3,267
|
7,646
|
||
Finance income and expense
|
445
|
502
|
||
Depreciation, amortisation and impairment
|
4,583
|
2,518
|
||
Decrease/(increase) in working capital and short-term provisions
|
166
|
(706)
|
||
Non-cash and other movements
|
258
|
(424)
|
||
Cash generated from operations
|
8,719
|
9,536
|
||
Interest paid
|
(475)
|
(545)
|
||
Tax paid
|
(844)
|
(2,043)
|
||
Net cash inflow from operating activities
|
7,400
|
6,948
|
||
Cash flows from investing activities
|
||||
Movement in short-term investments and fixed deposits
|
130
|
3,619
|
||
Purchase of property, plant and equipment
|
(742)
|
(672)
|
||
Disposal of property, plant and equipment
|
69
|
199
|
||
Purchase of intangible assets
|
(1,316)
|
(3,947)
|
||
Disposal of intangible assets
|
35
|
-
|
||
Purchase of non-current asset investments
|
(91)
|
(46)
|
||
Disposal of non-current asset investments
|
38
|
43
|
||
Acquisitions of business operations
|
(1,158)
|
(1,187)
|
||
Dividends received
|
-
|
7
|
||
Interest received
|
114
|
145
|
||
Payments made by subsidiaries to non-controlling interests
|
(10)
|
(20)
|
||
Payments received by subsidiaries from non-controlling interests
|
42
|
-
|
||
Net cash outflow from investing activities
|
(2,889)
|
(1,859)
|
||
Net cash inflow before financing activities
|
4,511
|
5,089
|
||
Cash flows from financing activities
|
||||
Proceeds from issue of share capital
|
482
|
429
|
||
Repurchase of shares
|
-
|
(2,635)
|
||
Issue of loans
|
-
|
1,980
|
||
Repayment of loans
|
-
|
(1,750)
|
||
Dividends paid
|
(3,461)
|
(3,665)
|
||
Hedge contracts relating to dividend payments
|
(36)
|
48
|
||
Repayment of obligations under finance leases
|
(27)
|
(17)
|
||
Movement in short-term borrowings
|
(5)
|
687
|
||
Net cash outflow from financing activities
|
(3,047)
|
(4,923)
|
||
Net increase in cash and cash equivalents in the period
|
1,464
|
166
|
||
Cash and cash equivalents at the beginning of the period
|
7,596
|
7,434
|
||
Exchange rate effects
|
(65)
|
(4)
|
||
Cash and cash equivalents at the end of the period
|
8,995
|
7,596
|
||
Cash and cash equivalents consists of:
|
||||
Cash and cash equivalents
|
9,217
|
7,701
|
||
Overdrafts
|
(222)
|
(105)
|
||
8,995
|
7,596
|
|||
* Restatement relates to the adoption of IAS 19 (2011), see Note 1.
|
Share
capital
$m
|
Share
premium
account
$m
|
Other
reserves*
$m
|
Retained
earnings
$m
|
Total
$m
|
Non-
controlling
interests
$m
|
Total
equity
$m
|
||||||||
At 1 Jan 2012**
|
323
|
3,078
|
1,951
|
17,888
|
23,240
|
226
|
23,466
|
|||||||
Profit for the period**
|
-
|
-
|
-
|
6,240
|
6,240
|
30
|
6,270
|
|||||||
Other comprehensive income**
|
-
|
-
|
-
|
155
|
155
|
(20)
|
135
|
|||||||
Transfer to other reserves
|
-
|
-
|
(5)
|
5
|
-
|
-
|
-
|
|||||||
Transactions with owners:
|
||||||||||||||
Dividends
|
-
|
-
|
-
|
(3,619)
|
(3,619)
|
-
|
(3,619)
|
|||||||
Issue of Ordinary Shares
|
3
|
426
|
-
|
-
|
429
|
-
|
429
|
|||||||
Repurchase of Ordinary Shares
|
(14)
|
-
|
14
|
(2,635)
|
(2,635)
|
-
|
(2,635)
|
|||||||
Share-based payments
|
-
|
-
|
-
|
(79)
|
(79)
|
-
|
(79)
|
|||||||
Transfer from non-controlling interests to payables
|
-
|
-
|
-
|
-
|
-
|
(10)
|
(10)
|
|||||||
Dividend paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
(11)
|
(11)
|
|||||||
Net movement
|
(11)
|
426
|
9
|
67
|
491
|
(11)
|
480
|
|||||||
At 31 Dec 2012**
|
312
|
3,504
|
1,960
|
17,955
|
23,731
|
215
|
23,946
|
|||||||
Share
capital
$m
|
Share
premium
account
$m
|
Other
reserves*
$m
|
Retained
earnings
$m
|
Total
$m
|
Non-
controlling
interests
$m
|
Total
equity
$m
|
||||||||
At 1 Jan 2013**
|
312
|
3,504
|
1,960
|
17,955
|
23,731
|
215
|
23,946
|
|||||||
Profit for the period
|
-
|
-
|
-
|
2,556
|
2,556
|
15
|
2,571
|
|||||||
Other comprehensive income
|
-
|
-
|
-
|
(86)
|
(86)
|
(27)
|
(113)
|
|||||||
Transfer to other reserves
|
-
|
-
|
6
|
(6)
|
-
|
-
|
-
|
|||||||
Transactions with owners:
|
||||||||||||||
Divdends
|
-
|
-
|
-
|
(3,499)
|
(3,499)
|
-
|
(3,499)
|
|||||||
Issue of Ordinary Shares
|
3
|
479
|
-
|
-
|
482
|
-
|
482
|
|||||||
Share-based payments
|
-
|
-
|
-
|
(57)
|
(57)
|
-
|
(57)
|
|||||||
Transfer from non-controlling interests to payables
|
-
|
-
|
-
|
-
|
-
|
(6)
|
(6)
|
|||||||
Dividend paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
(3)
|
(3)
|
|||||||
Net acquisition of non-controlling interests
|
-
|
-
|
-
|
97
|
97
|
(165)
|
(68)
|
|||||||
Net movement
|
3
|
479
|
6
|
(995)
|
(507)
|
(186)
|
(693)
|
|||||||
At 31 Dec 2013
|
315
|
3,983
|
1,966
|
16,960
|
23,224
|
29
|
23,253
|
At 1 Jan
2013
$m
|
Cash
Flow
$m
|
Non-cash
Movements
$m
|
Exchange
Movements
$m
|
At 31 Dec
2013
$m
|
||||||
Loans due after one year
|
(9,347)
|
-
|
888
|
(57)
|
(8,516)
|
|||||
Finance leases due after one year
|
(62)
|
-
|
(10)
|
-
|
(72)
|
|||||
Total long term debt
|
(9,409)
|
-
|
878
|
(57)
|
(8,588)
|
|||||
Current instalments of loans
|
-
|
-
|
(766)
|
-
|
(766)
|
|||||
Current instalments of finance leases
|
(22)
|
27
|
(35)
|
-
|
(30)
|
|||||
Total current debt
|
(22)
|
27
|
(801)
|
-
|
(796)
|
|||||
Other investments - current
|
823
|
(130)
|
88
|
15
|
796
|
|||||
Net derivative financial instruments
|
417
|
36
|
(51)
|
-
|
402
|
|||||
Cash and cash equivalents
|
7,701
|
1,578
|
-
|
(62)
|
9,217
|
|||||
Overdrafts
|
(105)
|
(114)
|
-
|
(3)
|
(222)
|
|||||
Short-term borrowings
|
(774)
|
5
|
-
|
(1)
|
(770)
|
|||||
8,062
|
1,375
|
37
|
(51)
|
9,423
|
||||||
Net (debt)/funds
|
(1,369)
|
1,402
|
114
|
(108)
|
39
|
4th Quarter
2013
$m
|
4th Quarter
2012
$m
|
Full Year
2013
$m
|
Full Year
2012
$m
|
|||||
Cost of sales
|
22
|
61
|
126
|
136
|
||||
Research and development expense
|
84
|
94
|
490
|
791
|
||||
Selling, general and administrative costs
|
279
|
243
|
805
|
631
|
||||
Total
|
385
|
398
|
1,421
|
1,558
|
Book value
$m
|
Fair value
adjustment
$m
|
Fair value
$m
|
||||
Non-current assets
|
||||||
Intangible assets
|
-
|
985
|
985
|
|||
Deferred tax assets
|
-
|
60
|
60
|
|||
-
|
1,045
|
1,045
|
||||
Current assets
|
12
|
-
|
12
|
|||
Current liabilities
|
(4)
|
-
|
(4)
|
|||
Non-current liabilities
|
||||||
Deferred tax liabilities
|
-
|
(379)
|
(379)
|
|||
-
|
(379)
|
(379)
|
||||
Total assets acquired
|
8
|
666
|
674
|
|||
Goodwill
|
44
|
|||||
Fair value of total consideration
|
718
|
|||||
Less: fair value of contingent consideration
|
(149)
|
|||||
Total upfront consideration
|
569
|
|||||
Less: cash and cash equivalents acquired
|
(4)
|
|||||
Net cash outflow
|
565
|
Book value
$m
|
Fair value
adjustment
$m
|
Fair value
$m
|
||||
Non-current assets
|
||||||
Intangible assets
|
-
|
526
|
526
|
|||
Deferred tax assets
|
-
|
18
|
18
|
|||
-
|
544
|
544
|
||||
Current assets
|
67
|
-
|
67
|
|||
Current liabilities
|
(10)
|
-
|
(10)
|
|||
Non-current liabilities
|
||||||
Deferred tax liabilities
|
-
|
(216)
|
(216)
|
|||
-
|
(216)
|
(216)
|
||||
Total assets acquired
|
57
|
328
|
385
|
|||
Goodwill
|
-
|
|||||
Fair value of total consideration
|
385
|
|||||
Less: fair value of contingent consideration
|
(62)
|
|||||
Upfront consideration
|
323
|
|||||
Less: cash acquired
|
(63)
|
|||||
Cash outflow
|
260
|
Book value
$m
|
Fair value
adjustment
$m
|
Fair value
$m
|
||||
Non-current assets
|
||||||
Intangible assets
|
-
|
534
|
534
|
|||
Property, plant and equipment
|
7
|
-
|
7
|
|||
Deferred tax assets
|
-
|
14
|
14
|
|||
7
|
548
|
555
|
||||
Current assets
|
17
|
-
|
17
|
|||
Current liabilities
|
(8)
|
-
|
(8)
|
|||
Non-current liabilities
|
||||||
Deferred tax liabilities
|
-
|
(219)
|
(219)
|
|||
-
|
(219)
|
(219)
|
||||
Total assets acquired
|
16
|
329
|
345
|
|||
Goodwill
|
33
|
|||||
Fair value of total consideration
|
378
|
|||||
Less: fair value of contingent consideration
|
(153)
|
|||||
Total upfront consideration
|
225
|
|||||
Less: cash and cash equivalents acquired
|
(17)
|
|||||
Less: deferred upfront consideration
|
(75)
|
|||||
Net cash outflow
|
133
|
Book value
$m
|
Fair value
adjustment
$m
|
Fair value
$m
|
||||
Non-current assets
|
||||||
Intangible assets
|
1
|
370
|
371
|
|||
Property, plant and equipment
|
1
|
-
|
1
|
|||
2
|
370
|
372
|
||||
Non-current liabilities
|
||||||
Deferred tax liabilities
|
-
|
(4)
|
(4)
|
|||
-
|
(4)
|
(4)
|
||||
Total assets acquired
|
2
|
366
|
368
|
|||
Goodwill
|
-
|
|||||
Fair value of total consideration
|
368
|
|||||
Less: fair value of contingent consideration
|
(168)
|
|||||
Total upfront consideration
|
200
|
|||||
Less: cash and cash equivalents acquired
|
-
|
|||||
Net cash outflow
|
200
|
Fair value
$m
|
|||
Non-current assets
|
|||
Intangible assets
|
5,762
|
||
Property, plant and equipment
|
490
|
||
6,252
|
|||
Current assets
|
478
|
||
Current liabilities
|
(262)
|
||
Non-current liabilities
|
(130)
|
||
Total assets acquired
|
6,338
|
||
Goodwill
|
1,565
|
||
Fair value of total consideration
|
7,903
|
||
Less: fair value of contingent consideration
|
(5,205)
|
||
Total upfront consideration
|
2,698
|
||
Less: cash and cash equivalents acquired
|
-
|
||
Net cash outflow
|
2,698
|
|
Nexium (esomeprazole magnesium)
|
|
As disclosed in the Government investigations section below, the US Attorney's Offices and all states, except for the State of Texas, have declined to intervene in the civil component of a previously disclosed investigation regarding Crestor. As a result, AstraZeneca has now been named as a defendant in a lawsuit filed in the US Federal Court in Wilmington, Delaware, under the qui tam (whistleblower) provisions of the federal False Claims Act and the Florida Whistleblower Act, alleging that AstraZeneca directed certain employees to promote Crestor off-label. AstraZeneca intends to vigorously defend this matter.
|
World
|
US
|
Europe
|
Established ROW
|
Emerging Markets
|
||||||||||||||||
FY 2013
$m
|
CER
%
|
FY 2013
$m
|
CER
%
|
FY 2013
$m
|
CER
%
|
FY 2013
$m
|
CER
%
|
FY 2013
$m
|
CER
%
|
|||||||||||
Cardiovascular:
|
||||||||||||||||||||
Crestor
|
5,622
|
(8)
|
2,912
|
(8)
|
1,225
|
(3)
|
807
|
(27)
|
678
|
17
|
||||||||||
Atacand
|
611
|
(39)
|
72
|
(52)
|
225
|
(52)
|
71
|
(49)
|
243
|
(1)
|
||||||||||
Seloken/Toprol-XL
|
750
|
(18)
|
131
|
(59)
|
130
|
(5)
|
24
|
(7)
|
465
|
8
|
||||||||||
Onglyza
|
378
|
17
|
265
|
12
|
56
|
12
|
20
|
54
|
37
|
61
|
||||||||||
Plendil
|
260
|
2
|
-
|
(100)
|
21
|
(17)
|
10
|
(17)
|
229
|
7
|
||||||||||
Tenormin
|
197
|
(7)
|
15
|
50
|
51
|
(6)
|
77
|
(13)
|
54
|
(7)
|
||||||||||
Brilinta/Brilique
|
283
|
216
|
73
|
284
|
163
|
179
|
17
|
n/m
|
30
|
210
|
||||||||||
Byetta
|
206
|
181
|
152
|
105
|
36
|
n/m
|
11
|
n/m
|
7
|
n/m
|
||||||||||
Bydureon
|
151
|
308
|
131
|
254
|
17
|
n/m
|
1
|
n/m
|
2
|
n/m
|
||||||||||
Forxiga
|
10
|
n/m
|
-
|
-
|
10
|
n/m
|
-
|
-
|
-
|
-
|
||||||||||
Others
|
362
|
4
|
50
|
100
|
164
|
(5)
|
25
|
(15)
|
123
|
2
|
||||||||||
Total Cardiovascular
|
8,830
|
(6)
|
3,801
|
(6)
|
2,098
|
(6)
|
1,063
|
(25)
|
1,868
|
11
|
||||||||||
Gastrointestinal:
|
||||||||||||||||||||
Nexium
|
3,872
|
-
|
2,123
|
(7)
|
360
|
(21)
|
597
|
41
|
792
|
8
|
||||||||||
Losec/Prilosec
|
486
|
(28)
|
30
|
-
|
131
|
(33)
|
165
|
(39)
|
160
|
(9)
|
||||||||||
Others
|
231
|
16
|
178
|
23
|
43
|
(5)
|
7
|
-
|
3
|
-
|
||||||||||
Total Gastrointestinal
|
4,589
|
(3)
|
2,331
|
(5)
|
534
|
(24)
|
769
|
9
|
955
|
5
|
||||||||||
Respiratory:
|
||||||||||||||||||||
Symbicort
|
3,483
|
10
|
1,233
|
23
|
1,502
|
1
|
423
|
7
|
325
|
17
|
||||||||||
Pulmicort
|
867
|
1
|
224
|
(4)
|
171
|
(13)
|
112
|
2
|
360
|
13
|
||||||||||
Others
|
327
|
(8)
|
58
|
(11)
|
115
|
(13)
|
33
|
(15)
|
121
|
1
|
||||||||||
Total Respiratory
|
4,677
|
7
|
1,515
|
16
|
1,788
|
(2)
|
568
|
4
|
806
|
13
|
||||||||||
Oncology:
|
||||||||||||||||||||
Zoladex
|
996
|
-
|
23
|
(4)
|
252
|
(8)
|
372
|
(4)
|
349
|
10
|
||||||||||
Iressa
|
647
|
11
|
-
|
-
|
177
|
11
|
202
|
9
|
268
|
14
|
||||||||||
Faslodex
|
681
|
6
|
324
|
5
|
221
|
(2)
|
62
|
21
|
74
|
29
|
||||||||||
Arimidex
|
351
|
(30)
|
6
|
(71)
|
93
|
(34)
|
154
|
(35)
|
98
|
(6)
|
||||||||||
Casodex
|
376
|
(7)
|
5
|
(267)
|
53
|
(13)
|
225
|
(10)
|
93
|
(4)
|
||||||||||
Others
|
142
|
15
|
25
|
-
|
29
|
53
|
60
|
14
|
28
|
4
|
||||||||||
Total Oncology
|
3,193
|
(2)
|
383
|
2
|
825
|
(6)
|
1,075
|
(7)
|
910
|
9
|
||||||||||
Neuroscience:
|
||||||||||||||||||||
Seroquel XR
|
1,337
|
(12)
|
743
|
(8)
|
416
|
(19)
|
71
|
(25)
|
107
|
12
|
||||||||||
Seroquel IR
|
345
|
(72)
|
(17)
|
n/m
|
105
|
(57)
|
106
|
(40)
|
151
|
(3)
|
||||||||||
Local Anaesthetics
|
510
|
(2)
|
-
|
-
|
206
|
(5)
|
182
|
(1)
|
122
|
2
|
||||||||||
Vimovo
|
91
|
42
|
20
|
(20)
|
32
|
41
|
20
|
50
|
19
|
400
|
||||||||||
Others
|
452
|
(9)
|
33
|
18
|
113
|
(25)
|
97
|
(16)
|
209
|
3
|
||||||||||
Total Neuroscience
|
2,735
|
(29)
|
779
|
(50)
|
872
|
(24)
|
476
|
(19)
|
608
|
6
|
||||||||||
Infection & Other:
|
||||||||||||||||||||
Synagis
|
1,060
|
2
|
617
|
1
|
443
|
4
|
-
|
-
|
-
|
-
|
||||||||||
Merrem
|
293
|
(24)
|
11
|
(71)
|
49
|
(42)
|
5
|
(72)
|
228
|
(8)
|
||||||||||
FluMist/Fluenz
|
245
|
35
|
199
|
14
|
42
|
n/m
|
4
|
33
|
-
|
(100)
|
||||||||||
Others
|
89
|
(5)
|
55
|
(5)
|
7
|
(63)
|
13
|
55
|
14
|
(17)
|
||||||||||
Total Infection & Other
|
1,687
|
(1)
|
882
|
-
|
541
|
3
|
22
|
(19)
|
242
|
(9)
|
||||||||||
Aptium Oncology
|
-
|
(100)
|
-
|
(100)
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||
Total
|
25,711
|
(6)
|
9,691
|
(9)
|
6,658
|
(9)
|
3,973
|
(10)
|
5,389
|
8
|
World
|
US
|
Europe
|
Established ROW
|
Emerging Markets
|
||||||||||||||||
Q4 2013
$m
|
CER
%
|
Q4 2013
$m
|
CER
%
|
Q4 2013
$m
|
CER
%
|
Q4 2013
$m
|
CER
%
|
Q4 2013
$m
|
CER
%
|
|||||||||||
Cardiovascular:
|
||||||||||||||||||||
Crestor
|
1,463
|
(8)
|
779
|
(10)
|
311
|
(3)
|
204
|
(19)
|
169
|
14
|
||||||||||
Atacand
|
134
|
(33)
|
10
|
(69)
|
54
|
(29)
|
13
|
(58)
|
57
|
(6)
|
||||||||||
Seloken/Toprol-XL
|
170
|
(32)
|
19
|
(81)
|
33
|
(9)
|
7
|
29
|
111
|
(3)
|
||||||||||
Onglyza
|
93
|
6
|
63
|
-
|
15
|
-
|
6
|
50
|
9
|
50
|
||||||||||
Plendil
|
66
|
3
|
-
|
-
|
6
|
(17)
|
3
|
-
|
57
|
6
|
||||||||||
Tenormin
|
46
|
(9)
|
3
|
50
|
13
|
(7)
|
19
|
(21)
|
11
|
9
|
||||||||||
Brilinta/Brilique
|
92
|
139
|
24
|
167
|
51
|
113
|
6
|
250
|
11
|
175
|
||||||||||
Byetta
|
54
|
17
|
36
|
(23)
|
11
|
n/m
|
4
|
n/m
|
3
|
n/m
|
||||||||||
Bydureon
|
49
|
88
|
40
|
54
|
6
|
n/m
|
1
|
n/m
|
2
|
n/m
|
||||||||||
Forxiga
|
3
|
n/m
|
-
|
-
|
3
|
n/m
|
-
|
-
|
-
|
-
|
||||||||||
Others
|
92
|
(4)
|
15
|
15
|
39
|
(12)
|
6
|
(40)
|
32
|
10
|
||||||||||
Total Cardiovascular
|
2,262
|
(8)
|
989
|
(14)
|
542
|
1
|
269
|
(18)
|
462
|
8
|
||||||||||
Gastrointestinal:
|
||||||||||||||||||||
Nexium
|
991
|
(3)
|
545
|
(9)
|
92
|
(12)
|
165
|
30
|
189
|
(5)
|
||||||||||
Losec/Prilosec
|
122
|
(18)
|
7
|
40
|
35
|
3
|
41
|
(36)
|
39
|
(7)
|
||||||||||
Others
|
55
|
2
|
42
|
14
|
10
|
(17)
|
2
|
-
|
1
|
(100)
|
||||||||||
Total Gastrointestinal
|
1,168
|
(5)
|
594
|
(7)
|
137
|
(9)
|
208
|
7
|
229
|
(6)
|
||||||||||
Respiratory:
|
||||||||||||||||||||
Symbicort
|
976
|
11
|
350
|
28
|
395
|
-
|
129
|
(1)
|
102
|
21
|
||||||||||
Pulmicort
|
245
|
3
|
59
|
5
|
44
|
(16)
|
34
|
5
|
108
|
10
|
||||||||||
Others
|
85
|
(12)
|
16
|
(11)
|
28
|
(13)
|
9
|
(23)
|
32
|
(6)
|
||||||||||
Total Respiratory
|
1,306
|
7
|
425
|
22
|
467
|
(3)
|
172
|
(1)
|
242
|
12
|
||||||||||
Oncology:
|
||||||||||||||||||||
Zoladex
|
247
|
1
|
5
|
-
|
60
|
(13)
|
96
|
(5)
|
86
|
23
|
||||||||||
Iressa
|
158
|
5
|
-
|
-
|
45
|
2
|
53
|
2
|
60
|
11
|
||||||||||
Faslodex
|
182
|
6
|
87
|
5
|
58
|
(4)
|
17
|
10
|
20
|
40
|
||||||||||
Arimidex
|
86
|
(23)
|
4
|
-
|
22
|
(19)
|
38
|
(33)
|
22
|
-
|
||||||||||
Casodex
|
95
|
(4)
|
2
|
-
|
13
|
(7)
|
57
|
(6)
|
23
|
-
|
||||||||||
Others
|
40
|
19
|
7
|
17
|
9
|
50
|
18
|
22
|
6
|
(14)
|
||||||||||
Total Oncology
|
808
|
-
|
105
|
7
|
207
|
(6)
|
279
|
(7)
|
217
|
15
|
||||||||||
Neuroscience:
|
||||||||||||||||||||
Seroquel XR
|
337
|
(12)
|
194
|
(9)
|
104
|
(15)
|
11
|
(56)
|
28
|
21
|
||||||||||
Seroquel IR
|
35
|
(64)
|
(19)
|
n/m
|
24
|
(31)
|
(2)
|
n/m
|
32
|
3
|
||||||||||
Local Anaesthetics
|
132
|
(1)
|
-
|
-
|
53
|
(2)
|
49
|
4
|
30
|
(6)
|
||||||||||
Vimovo
|
24
|
39
|
3
|
(50)
|
9
|
14
|
6
|
40
|
6
|
-
|
||||||||||
Others
|
114
|
(4)
|
9
|
29
|
27
|
(7)
|
24
|
(17)
|
54
|
2
|
||||||||||
Total Neuroscience
|
642
|
(14)
|
187
|
(13)
|
217
|
(13)
|
88
|
(38)
|
150
|
8
|
||||||||||
Infection & Other:
|
||||||||||||||||||||
Synagis
|
515
|
2
|
300
|
(1)
|
215
|
8
|
-
|
-
|
-
|
-
|
||||||||||
Merrem
|
77
|
(25)
|
2
|
(89)
|
11
|
(39)
|
-
|
(100)
|
64
|
-
|
||||||||||
FluMist/Fluenz
|
50
|
56
|
22
|
(24)
|
26
|
n/m
|
2
|
100
|
-
|
(100)
|
||||||||||
Others
|
16
|
(28)
|
10
|
(47)
|
-
|
-
|
5
|
n/m
|
1
|
(70)
|
||||||||||
Total Infection & Other
|
658
|
-
|
334
|
(10)
|
252
|
14
|
7
|
n/m
|
65
|
(10)
|
||||||||||
Aptium Oncology
|
-
|
(100)
|
-
|
(100)
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||
Total
|
6,844
|
(4)
|
2,634
|
(7)
|
1,822
|
(2)
|
1,023
|
(10)
|
1,365
|
6
|
First interim
|
Announced with second quarter and half year results and paid in September
|
Second interim
|
Announced with fourth quarter and full year results and paid in March
|
Registrar and
Transfer Office
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
UK
|
US Depositary
JP Morgan Chase & Co
PO Box 64504
St Paul
MN 55164-0504
US
|
Registered Office
2 Kingdom Street
London
W2 6BD
UK
|
Swedish Central Securities Depository
Euroclear Sweden AB
PO Box 191
SE-101 23 Stockholm
Sweden
|
Tel (freephone in UK):
0800 389 1580
Tel (outside UK):
+44 (0)121 415 7033
|
Tel (toll free in US):
888 697 8018
Tel (outside US):
+1 651 453 2128
|
Tel: +44 (0) 20 7604 8000
|
Tel: +46 (0)8 402 9000
|
Date: 06 February 2014
|
By: /s/ Adrian Kemp
|
Name: Adrian Kemp
|
|
Title: Company Secretary
|